Funding the Science That Defines the Future
We invest across the full spectrum of celiac disease innovation, supporting breakthroughs emerging from rapid advances in disease biology and translational research. Our modality-agnostic strategy spans diagnostics, therapeutics, and enabling technologies designed to accelerate prevention, treatment, and long-term disease management.
We prioritize opportunities grounded in strong scientific rationale and scalable commercial pathways, directing capital to areas of highest unmet clinical need.
Investment Strategy
Science-led investing, executed with venture discipline
Our Process: A Structured Approach to Building Value
Opportunities are evaluated continuously through a disciplined framework aligned with portfolio strategy and mission objectives. Following investment, we remain actively engaged through governance participation, strategic guidance, and access to our global network of celiac disease experts.
Diligence
Deep scientific and commercial diligence conducted in global collaboration with leading clinicians and researchers evaluates each investment for translational feasibility, technical risk, and long-term value creation.
Technology Focus
We invest across diverse therapeutic and diagnostic modalities, including enzymatic therapies, immunomodulation, microbiome science, barrier restoration, and next-generation diagnostic platforms.
R&D Strategy
Stage-agnostic investing from discovery through clinical development, prioritizing assets supported by strong mechanistic rationale and early disease-specific validation.
Financing Structure
Flexible investment structures in both private and public companies, often in partnership with co-investors to accelerate development and scale impact.
Venture Philanthropy with Institutional Discipline
We deploy capital through a venture philanthropy model that applies the analytical rigor and execution standards of a traditional venture capital platform. Investments undergo institutional-grade scientific and commercial diligence and are frequently syndicated alongside experienced biotechnology investors.
Financial returns are reinvested to expand the pipeline of high-potential opportunities, creating a compounding capital flywheel that strengthens the global celiac innovation ecosystem.
Our portfolio targets differentiated disease-modifying therapies, advanced diagnostic platforms, and technologies addressing persistent unmet needs, including refractory and non-responsive celiac disease. Investments are global in scope.